Checkmate Pharmaceuticals, Inc. CMPI
10.50 +10.50
Day range unavailable
52-week range unavailable
- Market cap
- 231.40M
- Shares out
- 22.04M
- Forward P/E
- -4.61
- Analysts
- Buy
- Price target
- 12.50 (+19.0%)
- Earnings date
- May 12, 2022
No chart data for this range yet.
Key statistics
- Enterprise value
- 171.37M
- PEG ratio
- -0.08
- Price / sales
- 0.00
- Price / book
- 4.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.72M
- Total cash
- 60.03M
- Total debt
- 0
- Return on equity
- -75.44%
- Short % of float
- 0.52%
- 50-day average
- 8.60
- 200-day average
- 4.78
Analyst view
Consensus: buy
Buy
Price target (mean) 12.50 +19.0% upside
Now 10.50
- Target (low)
- 6.00
- Target (mean)
- 12.50
- Target (high)
- 19.00
Ratings (-1m) 3 3 buy · 0 hold · 0 sell
- Strong buy3
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 12, 2022
Expected May 12, 2022. Consensus EPS estimate -0.75.
Financials — quick view
CMPI Revenue — quarterly 0
CMPI Net income — quarterly -15.87M
CMPI EPS — quarterly -0.73
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2022 | Mar 1, 2022 | -0.73 | — | — | — |
| Mar 29, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 12, 2021 | Sep 1, 2021 | -0.71 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.94 | — | — | — |
| May 13, 2021 | Mar 1, 2021 | -0.75 | — | — | — |
| Apr 2, 2021 | Dec 1, 2020 | -0.49 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2022 | BTIG | down | Buy | Neutral |
| Mar 30, 2022 | BTIG | main | — | Buy |
| Oct 6, 2021 | B of A Securities | up | Neutral | Buy |
| Sep 1, 2020 | Bank of America | init | — | Neutral |
| Sep 1, 2020 | Jefferies | init | — | Buy |
| Sep 1, 2020 | BTIG | init | — | Buy |
About Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- checkmatepharma.com
News
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment 
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI 
CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, FSI, TWTR 
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout 
SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc. 
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today 
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today? 
Why Checkmate Pharmaceuticals Shares Are Skyrocketing 
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Your note
Sign in to keep a note on CMPI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAUDHARY KLEEM | Officer | Conversion of Exercise of derivative security | Feb 25, 2021 | 8,000 |
| KRIEG ARTHUR M | Officer | Purchase | Jun 17, 2021 | 815,734 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 24, 2022 | 2,161,990 |
| POWELL MICHAEL | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 10, 2020 | 0 |
| VENBIO GLOBAL STRATEGIC FUND, II, L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | May 15, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| venBio Partners LLC | 16.67% | 3,673,374 | 11.72M | Mar 30, 2022 |
| Sofinnova Investments, Inc. | 16.37% | 3,606,707 | 11.51M | Mar 30, 2022 |
| Novo Holdings A/S | 9.81% | 2,161,990 | 6.90M | Mar 30, 2022 |
| Medicxi Ventures Management (Jersey) Ltd | 6.81% | 1,501,716 | 4.79M | Mar 30, 2022 |
| Omega Fund Management, Llc | 6.06% | 1,335,050 | 4.26M | Mar 30, 2022 |
| Decheng Capital Management III (Cayman), LLC | 6.05% | 1,333,254 | 4.25M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Clough Global Opportunities Fund | 2.89% | 637,346 | 1.56M | Jan 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.40% | 528,940 | 1.52M | Dec 30, 2021 |
| Clough Global Equity Fund | 1.50% | 330,872 | 807.33K | Jan 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.47% | 103,800 | 331.12K | Mar 30, 2022 |
| Clough Global Long/Short Fund | 0.25% | 55,942 | 136.50K | Jan 30, 2022 |
| Vanguard Extended Market Index Fund | 0.19% | 41,483 | 119.06K | Dec 30, 2021 |